Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics.
暂无分享,去创建一个
P Ubezio | G Tagliabue | Z. Agur | G. Tagliabue | P. Ubezio | Z Agur | B Schechter | B. Schechter
[1] G. Neil,et al. The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors. , 1973, Cancer research.
[2] T. Dexter,et al. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. , 1991, Blood.
[3] M. McKeel,et al. Differential analysis of animal bone marrow by flow cytometry. , 1992, Cytometry.
[4] S. Shackney,et al. ViVACCy—A Drug Schedule Based on G2 Blockade and Prolonged Infusion of Multiple Tubulin‐Binding Agents A Pilot Study , 1990, Cancer.
[5] J. Gray. Flow cytometry and cell kinetics: relation to cancer therapy , 1981 .
[6] I. Weissman,et al. Mouse hematopoietic stem cells. , 1991, Blood.
[7] J. Gray,et al. Ara-C scheduling: theoretical and experimental considerations. , 1982, Medical and pediatric oncology.
[8] Z. Agur,et al. Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. , 1992, European journal of cancer.
[9] I. Tannock,et al. Cell kinetics and chemotherapy: a critical review. , 1978, Cancer treatment reports.
[10] G. Wilson,et al. The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. , 1985, Cytometry.
[11] S. Kuentzel,et al. Cell-kill kinetics of several S-phase-specific drugs. , 1973, Cancer research.
[12] Z. Agur,et al. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. , 1992, Mathematical biosciences.